Therefore, METTL1/WDR4-dominated m7G modification of tRNA drives the pathogenesis process through remodeling of mRNA translation activities to enhance the expression of cell cycle progression genes, which may represent a novel target for AML treatment. The gene discussed is METTL1; the disease is acute myeloid leukemia.